Diabetes mellitus and chronic liver diseases. Literature review (part 2) : treatment features
Diabetes mellitus (DM) and chronic liver disease (CLD) are pathological conditions associated with each other and reaching epidemic proportions. There is a strong pathogenetic relationship of carbohydrate metabolism disorders and a number of CLD. Common mechanisms that provoke metabolic and autoimmune disorders in the development of various CLD, leading to steatosis, insulin resistance (IR), impaired glucose tolerance and the development of DM are described. Effective glycemic control can have a beneficial effect on the treatment of these patients, and, conversely, there is evidence of a positive effect of CLD therapy on carbohydrate metabolism. This review discusses the correction of carbohydrate metabolism in patients with CLD, the main groups of modern hypoglycemic drugs, mechanisms of their action, the impact on the physiology of the liver, the possibility of using each of these pharmacological groups in patients with impaired liver function. The modern approaches and possibilities of drug effects on the process of fibrogenesis in CLD, the effect of these drugs on carbohydrate metabolism are listed.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:91 |
|---|---|
| Enthalten in: |
Terapevticheskii arkhiv - 91(2019), 12 vom: 15. Dez., Seite 115-121 |
| Sprache: |
Russisch |
|---|
| Beteiligte Personen: |
Kalmykova, Z A [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 28.08.2020 Date Revised 28.08.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.26442/00403660.2019.12.000166 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM311766749 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM311766749 | ||
| 003 | DE-627 | ||
| 005 | 20231225142948.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.26442/00403660.2019.12.000166 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1039.xml |
| 035 | |a (DE-627)NLM311766749 | ||
| 035 | |a (NLM)32598598 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 100 | 1 | |a Kalmykova, Z A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diabetes mellitus and chronic liver diseases. Literature review (part 2) |b treatment features |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 28.08.2020 | ||
| 500 | |a Date Revised 28.08.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Diabetes mellitus (DM) and chronic liver disease (CLD) are pathological conditions associated with each other and reaching epidemic proportions. There is a strong pathogenetic relationship of carbohydrate metabolism disorders and a number of CLD. Common mechanisms that provoke metabolic and autoimmune disorders in the development of various CLD, leading to steatosis, insulin resistance (IR), impaired glucose tolerance and the development of DM are described. Effective glycemic control can have a beneficial effect on the treatment of these patients, and, conversely, there is evidence of a positive effect of CLD therapy on carbohydrate metabolism. This review discusses the correction of carbohydrate metabolism in patients with CLD, the main groups of modern hypoglycemic drugs, mechanisms of their action, the impact on the physiology of the liver, the possibility of using each of these pharmacological groups in patients with impaired liver function. The modern approaches and possibilities of drug effects on the process of fibrogenesis in CLD, the effect of these drugs on carbohydrate metabolism are listed | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a alcoholic liver disease | |
| 650 | 4 | |a chronic liver disease | |
| 650 | 4 | |a diabetes mellitus | |
| 650 | 4 | |a hypoglycemic agents | |
| 650 | 4 | |a liver cirrhosis | |
| 650 | 4 | |a liver failure | |
| 650 | 4 | |a nonalcoholic fatty liver disease | |
| 650 | 4 | |a viral hepatitis | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 650 | 7 | |a Blood Glucose |2 NLM | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 700 | 1 | |a Kononenko, I V |e verfasserin |4 aut | |
| 700 | 1 | |a Mayorov, A Y |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Terapevticheskii arkhiv |d 1949 |g 91(2019), 12 vom: 15. Dez., Seite 115-121 |w (DE-627)NLM000055425 |x 0040-3660 |7 nnns |
| 773 | 1 | 8 | |g volume:91 |g year:2019 |g number:12 |g day:15 |g month:12 |g pages:115-121 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.26442/00403660.2019.12.000166 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 91 |j 2019 |e 12 |b 15 |c 12 |h 115-121 | ||